A dial between the liver and the bloodstream
In the ongoing human struggle against heart disease, researchers at UT Southwestern have found an unexpected guardian hidden within the liver's own genetic machinery — a protein called HELZ2 that governs how much harmful cholesterol ever enters the bloodstream, not by intercepting it mid-journey, but by quietly erasing the instructions to make it in the first place. Published in Circulation, the discovery reframes cholesterol as a problem of origins rather than consequences, suggesting that medicine has long been arriving to a fire it could have prevented. The finding carries both promise and caution, as nature's own balancing act between blood cholesterol and liver fat reminds us that biological systems rarely yield simple solutions.
- Heart disease remains one of humanity's leading killers, and statins — the reigning treatment — work far downstream from where the real trouble begins.
- HELZ2 was discovered almost by accident, surfacing during an investigation into unusual liver fat in mice, its significance only revealed through a Nobel laureate's large-scale genetic screening system.
- Mice with heightened HELZ2 activity produced dramatically less LDL cholesterol and showed stronger protection against arterial clogging — but paid a price in accumulated liver fat, exposing a biological trade-off that complicates easy optimism.
- The protein operates at the messenger RNA level, degrading the genetic instructions for apoB before cholesterol-carrying particles can even be assembled — a fundamentally earlier intervention than any existing therapy.
- Researchers now face the challenge of threading a needle: modulating HELZ2 precisely enough to lower dangerous blood cholesterol without tipping the liver toward disease, a balance that could reshape treatment for both heart disease and fatty liver conditions affecting a quarter of the world's population.
Researchers at UT Southwestern have identified a protein called HELZ2 that acts as an early-stage control point for cholesterol production — one that operates before cholesterol-carrying particles ever reach the bloodstream. The discovery, published in Circulation, suggests a fundamentally different approach to managing the cholesterol levels that underlie heart disease.
For decades, the dominant strategy has been to intervene after cholesterol is already in circulation. Statins block the body's ability to synthesize cholesterol, but HELZ2 acts even earlier — at the level of messenger RNA, the temporary genetic instructions liver cells use to build apoB, the foundational protein in cholesterol-carrying particles. When HELZ2 activity rises, the apoB message degrades faster, fewer proteins are assembled, and fewer particles enter the blood.
The team stumbled onto HELZ2 while investigating unusual fat accumulation in mouse livers, using a genetic screening system developed by Nobel laureate Bruce Beutler. Mice carrying a mutation that boosted HELZ2 activity showed significantly lower LDL cholesterol and triglycerides, along with greater protection against atherosclerosis. Senior author Zhao Zhang described it as a powerful dial in the body's cholesterol regulation.
Yet the discovery also revealed a complicating trade-off: the same mice that benefited from lower blood cholesterol accumulated more fat in their livers. The inverse held true as well — less HELZ2 activity meant higher blood cholesterol but less hepatic fat. Rather than reducing total cholesterol, HELZ2 appears to redistribute it between the bloodstream and the liver.
That delicate balance makes the protein a compelling but demanding drug target. A therapy that modulates HELZ2 could prevent apoB proteins from being made at all — a genuinely upstream intervention — while potentially offering new strategies for fatty liver disease, a condition affecting roughly a quarter of the global population with few effective treatments. The finding invites medicine to think about cholesterol not as a downstream problem to be managed, but as a process that can be shaped before it truly begins.
Researchers at UT Southwestern have identified a protein that acts as an unexpected control point for cholesterol production, one that works at a stage long before the cholesterol-carrying particles ever reach the bloodstream. The protein, called HELZ2, operates by destabilizing the genetic instructions that cells use to manufacture apoB, a foundational component of the particles responsible for ferrying cholesterol and fats through the body. The discovery, published in Circulation, the journal of the American Heart Association, suggests a fundamentally different way to manage the cholesterol levels that drive heart disease.
For decades, researchers have focused on what happens to cholesterol after it has already been produced and released into circulation. Statins, the most widely prescribed cholesterol drugs, work by interfering with the body's ability to manufacture cholesterol itself. But the UT Southwestern team found something unexpected: HELZ2 intercepts the process even earlier, at the level of messenger RNA—the temporary genetic instruction set that tells liver cells how to build apoB proteins. When HELZ2 activity increases, the apoB message degrades faster, meaning fewer of these proteins get made in the first place, and consequently fewer cholesterol-carrying particles enter the blood.
The researchers made this discovery while investigating unusual fat accumulation in the livers of laboratory mice. Using a large-scale genetic screening system developed by Bruce Beutler, a Nobel Prize winner who directs the Center for the Genetics of Host Defense at UT Southwestern, the team identified a mutation that boosted HELZ2 activity. Mice carrying this mutation produced significantly less LDL cholesterol and triglycerides in their bloodstream and showed greater protection against atherosclerosis, the arterial clogging disease underlying most heart attacks and strokes. Zhao Zhang, the study's senior author and an assistant professor at UT Southwestern, described HELZ2 as a powerful control point—a place where the body's cholesterol regulation could be adjusted.
But the discovery revealed a trade-off that complicates any simple therapeutic strategy. While the mutant mice benefited from lower blood cholesterol, they accumulated more fat in their livers. Mice without the mutation showed the opposite pattern: higher blood cholesterol but less liver fat. This inverse relationship suggests that HELZ2 functions like a dial, shifting cholesterol between two compartments—the bloodstream and the liver—rather than simply reducing the total amount of cholesterol in the body. Zhang likened it to a valve between two chambers: turning it up lowers blood cholesterol but increases hepatic fat storage; turning it down reverses both effects.
That delicate balance makes HELZ2 particularly intriguing as a potential drug target, precisely because it operates at a different point in the cholesterol production pipeline than existing therapies. Rather than blocking cholesterol synthesis or modifying cholesterol particles after they have been made, a drug that modulates HELZ2 could prevent apoB proteins from being manufactured at all. Researchers believe that carefully adjusting HELZ2 activity might eventually lower dangerous cholesterol levels while also offering new approaches to fatty liver disease, a condition affecting roughly a quarter of the global population and for which few effective treatments exist. The finding represents a shift in how scientists think about cholesterol regulation—not as a problem to be solved downstream, after the particles are already in circulation, but as a process that can be controlled at the genetic instruction stage, before production even begins.
Citações Notáveis
HELZ2 acts as a powerful control point for how many cholesterol-carrying particles ultimately enter the bloodstream.— Zhao Zhang, Ph.D., Assistant Professor at UT Southwestern
The idea that we can control apoB at the RNA level represents a major shift in how we think about cholesterol regulation.— Zhao Zhang, Ph.D.
A Conversa do Hearth Outra perspectiva sobre a história
So HELZ2 stops cholesterol before it's made, rather than after. Why does that distinction matter so much?
Because it's a different lever entirely. Statins are like trying to clean up a spill that's already happening. HELZ2 is like turning off the faucet before the water runs. You're preventing the problem at the source.
But the mice with more HELZ2 activity got fatty livers. That sounds like trading one problem for another.
Exactly. That's the real puzzle. It's not a simple on-off switch. The body seems to be balancing cholesterol between the blood and the liver. If you push cholesterol out of the blood, it accumulates in the liver instead. We don't yet know if that trade-off is acceptable in humans, or if we can find a way to adjust it.
Could this eventually replace statins?
Not necessarily replace them, but offer an alternative path. Some people don't tolerate statins well, or they don't respond to them. A drug targeting HELZ2 would work through a completely different mechanism. You might use it alone, or combine it with other approaches.
What's the timeline before this becomes a treatment?
That's the honest question. They've identified the mechanism in mice. The next steps are understanding whether it works the same way in humans, and then whether you can safely modulate it without causing liver damage or other side effects. Years of work ahead.